These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 1703823

  • 1. [Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII].
    Weippert M, Anders O, Schmidt M, Roewer J.
    Beitr Infusionsther; 1990; 26():174-8. PubMed ID: 1703823
    [Abstract] [Full Text] [Related]

  • 2. Disappearance of factor VIII antibodies upon frequent administration of factor VIII.
    Mauser-Bunschoten EP, Roosendaal G, Bruin M, van Dijken PJ.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):533-7. PubMed ID: 1714856
    [Abstract] [Full Text] [Related]

  • 3. [Suppression of factor VIII inhibitor in children with hemophilia A].
    Zenz W, Muntean W.
    Padiatr Padol; 1987; 22(4):345-52. PubMed ID: 3125510
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated.
    Scheibel E, Ingerslev J, Dalsgaard-Nielsen J, Stenbjerg S, Knudsen JB.
    Thromb Haemost; 1987 Dec 18; 58(4):1049-52. PubMed ID: 3127918
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A, Zieleniewska B.
    Acta Haematol Pol; 1994 Dec 18; 25(4):349-54. PubMed ID: 7847036
    [Abstract] [Full Text] [Related]

  • 11. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J, Skulimowska J, Windyga J, Lopaciuk S, Kościelak J.
    Arch Immunol Ther Exp (Warsz); 2005 Dec 18; 53(4):352-6. PubMed ID: 16088320
    [Abstract] [Full Text] [Related]

  • 12. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A.
    Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, Haan E, Kruitwagen CL, Sixma JJ, van den Berg HM.
    Thromb Haemost; 2000 Jan 18; 83(1):65-9. PubMed ID: 10669157
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R.
    Ther Drug Monit; 2007 Feb 18; 29(1):20-6. PubMed ID: 17304146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.